Balyasny Asset Management
BIO icon

Balyasny Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Balyasny Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$11.2M – 2243
2021
Q3 		$11.2M Buy
+15,000
New +$11.2M 0.05% 526

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's BIO Position: Q1 2025 in Review

Balyasny Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 47,073 shares — an estimated $15.5M sold.

Balyasny Asset Management first reported a position in BIO in Q3 2015 and held it in 19 quarters. The position peaked at $46.6M in Q1 2022. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Balyasny Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 47,073 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $15.5M.
  • Balyasny Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and held it in 19 quarters.
  • Balyasny Asset Management's Bio-Rad Laboratories Class A position peaked at $46.6M in Q1 2022.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.